文献速递神经肿瘤

高通量体外药物筛选与体内研究确定芬维A胺为穿透血脑屏障的DMG治疗药物

High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic.
PubMed 文献 · Neuro Oncol · 2025-01-01

研究采用高通量药物筛选针对H3K27改变的弥漫性中线胶质瘤(DMG)神经球,发现6种化合物具细胞毒性,但多数因血脑屏障穿透有限未能改善原位模型生存;芬维A胺可有效穿透血脑屏障并显著延长荷瘤动物生存,机制涉及增加活性氧、抑制PDGFRα诱导凋亡及上调未折叠蛋白反应与内质网应激通路。

要点

  • 高通量筛选鉴定6种对DMG神经球有细胞毒性的化合物。
  • 多数化合物因血脑屏障穿透有限未改善原位DMG模型生存。
  • 芬维A胺可穿透血脑屏障并显著延长荷瘤动物生存。

核心结论

  • 本研究识别了DMG新的治疗脆弱点,并强调芬维A胺是穿透血脑屏障的抗DMG药物。

研究设计与样本

  • 采用高通量药物筛选针对DMG神经球测试具生物活性、临床已批准的化合物。
  • 利用多种原代DMG培养结合体外细胞毒性与克隆形成实验验证候选化合物。
  • 采用分子多样性的患者来源与转基因DMG原位模型评估疗效,并进行药代动力学与免疫组化分析。
  • 通过RNA测序、蛋白质印迹与流式细胞术探讨芬维A胺在DMG细胞中的抗肿瘤机制。

主要发现

  • 高通量筛选鉴定并验证6种化合物具强细胞毒性。
  • 多数化合物因血脑屏障穿透有限未能改善原位DMG模型生存。
  • 芬维A胺显示有效血脑屏障穿透并显著延长荷瘤动物生存。
  • 芬维A胺增加活性氧生成并通过抑制PDGFRα诱导凋亡。
  • RNA测序显示芬维A胺上调未折叠蛋白反应与内质网应激通路、下调神经发生。

关键数值与推荐

  • 高通量筛选鉴定6种化合物具强细胞毒性。
  • 芬维A胺在PDGFRα扩增与转基因DMG模型中显示体内抗肿瘤疗效。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse midline glioma, characterized by H3K27 alteration (DMG), is the predominant high-grade glioma in children. It commonly originates in the brainstem, yet effective treatments for these patients remain elusive. METHODS: To identify novel therapies for DMG, we conducted high-throughput drug screens (HTS) using biologically active, clinically approved compounds against DMG neurospheres. Multiple primary DMG cultures were utilized in conjunction with in vitro cytotoxicity and clonogenic assays to validate the efficacy of top compounds. Molecularly diverse patient-derived and transgenic DMG orthotopic models were employed to assess therapeutic efficacy alongside pharmacokinetic and immunohistochemical analyses. Mechanistic studies, including RNA sequencing, western blotting, and flow cytometry, were conducted to elucidate the antitumor efficacy of the most promising compound, fenretinide, in DMG cells. RESULTS: Through HTS, 6 compounds were identified and validated for their potent cytotoxic activity. However, most of these compounds failed to improve survival in an orthotopic Diffuse Midline Glioma (DMG) model due to limited blood-brain barrier (BBB) penetration. In contrast, fenretinide exhibited effective BBB penetration, significantly enhancing the survival of tumor-bearing animals. Mechanistic studies revealed that fenretinide increased reactive oxygen species (ROS) generation and induced apoptosis by inhibiting PDGFRα. RNA-sequencing further elucidated that fenretinide upregulates the Unfolded Protein Response (UPR) and endoplasmic reticulum (ER) stress pathways while downregulating neurogenesis. The in vivo antitumor efficacy of 2 fenretinide formulations was demonstrated in PDGFRα-amplified and transgenic DMG models. CONCLUSION: This comprehensive study has identified new DMG therapeutic vulnerabilities and highlights fenretinide as a brain-penetrant, anti-DMG agent.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Upton DH, Liu J, George SM, et al. High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic. Neuro Oncol. 2025. PMID: 39935375. doi:10.1093/neuonc/noaf035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。